A growing prevalence of hypoparathyroidism, rising patient and healthcare professional awareness, and improvements in treatment options have all contributed to the Hypoparathyroidism Treatment Market experiencing tremendous growth in recent years. A uncommon endocrine condition called hypoparathyroidism is characterised by insufficient parathyroid hormone production or activity, which causes an imbalance in the body’s calcium and phosphorus levels. Effective treatment choices are essential because this ailment can have crippling impacts on patients’ quality of life.
The landscape of treatments for hypoparathyroidism has undergone some major changes lately. The long-standing mainstays of therapy, such as calcium and vitamin D supplementation, are being complemented by more recent methods. Recombinant parathyroid hormone (PTH) therapy, which tries to treat the condition’s underlying cause by giving patients the hormone they are missing, is one of the most encouraging advancements.
Explore The Path to Success and Prosperity with Our Sample Report – Get Your Copy Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-7857
The market for treating hypoparathyroidism was estimated to be worth US$ 777.4 million in 2022 and is anticipated to grow to US$ 841.9 million in 2023. The market is anticipated to grow at a CAGR of 7.7% from 2023 to 2033, reaching a projected value of US$ 1,767.4 million at the end of the forecast period.
The market for hypoparathyroidism treatment is also benefiting from increased research and development activities, resulting in innovative therapies and drug formulations. Moreover, the regulatory landscape has become more favorable, expediting the approval process for new treatments. As a result, pharmaceutical companies are increasingly investing in this niche market, further fueling its growth.
However, challenges persist, such as the high cost of newer treatments and limited awareness among patients and healthcare providers about the available therapies. These factors can hinder market growth to some extent. Nonetheless, the Hypoparathyroidism Treatment Market is poised for continued expansion as more patients receive accurate diagnoses, and innovative therapies become more accessible, ultimately improving the lives of those affected by this rare endocrine disorder.
Key Takeaways:
- Over the next several decades, the Indian market is expected to grow at an 8.6% CAGR.
- By 2033, the worldwide market is expected to be worth US$ 1767.4 million.
- The United States has emerged as the dominant market, accounting for more than 37.7% of overall demand in 2022.
- Over the next several decades, the Chinese market is expected to grow at a CAGR of 7.9%.
- In 2022, the calcium supplements category accounted for 38.29% of market revenue.
“As patient awareness grows, the market is projected to see a rise in patient screening for a variety of thyroid diseases. Furthermore, the approval and classification of hypothyroidism medications as orphan pharmaceuticals by the US Food and Drug Administration (FDA) and the European Commission (EC), along with the untapped patient pool, is projected to boost market development,” says the FMI analyst
Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-7857
Competitive Landscape:
- Amolyt Pharma revealed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023 in May 2023. The presentation highlights the potential benefits of eneboparatide as a treatment for hypoparathyroidism, an illness in which numerous individuals have or are at risk of developing osteopenia and osteoporosis.
- In November 2022, the Food and Drug Administration (FDA) authorized for Priority Assessment a new drug application (NDA) for TransConTM PTH (palopegteriparatide) in adults with hypoparathyroidism.
Key Companies Profiled:
- Takeda Pharmaceutical Company Limited.
- Entera Bio Ltd.
- Amgen Inc.
- Ascendis Pharma A/S
- F. Hoffmann-La Roche Ltd
- ProLynx, Inc.
- Extend Biosciences, Inc.
- BionPharma Inc.
- Teva Pharmaceuticals Ltd.
Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-7857
Hypoparathyroidism Treatment Market Segmentation:
By Product Type:
- Parathyroid Hormone
- Natpara
- Others
- Vitamin D Analogue
- Vitamin D2
- Vitamin D3
- Calcium Supplements
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
For In-Depth Competitive Analysis, Purchase this Report! https://www.futuremarketinsights.com/checkout/7857
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
